SCHEMBL146609

SCHEMBL146609

CCC1=C(C(N)=O)C(=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 1.00
FGFR2 P21802 8/20 1.00
FGFR4 P22455 8/20 1.00
FGFR3 P22607 8/20 1.00
SRC P12931 4/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
ALDH1A1 P00352 7/20 0.42
LMNA P02545 6/20 0.42
MAPT P10636 6/20 0.42
HPGD P15428 4/20 0.42
NPSR1 Q6W5P4 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALOX12 P18054 3/20 0.42
HTT P42858 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
PKM P14618 1/20 0.42
STAT3 P40763 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5491718 0.80 FGFR1 (0.68) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL30004167 0.74 FGFR1 (0.57) FGFR1FGFR2FGFR4FGFR3ALDH1A1
SCHEMBL5820931 0.74 FGFR1 (0.57) FGFR1FGFR2FGFR4FGFR3ALDH1A1
SCHEMBL16453655 0.73 APAF1 (0.60) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL1210571 0.73 FGFR1 (0.59) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL9247351 0.72 FGFR1 (0.57) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL8781044 0.69 APAF1 (0.60) FGFR1FGFR2FGFR4FGFR3ALDH1A1
SCHEMBL21814476 0.69 FGFR1 (0.53) FGFR1FGFR2FGFR4FGFR3ALDH1A1
SCHEMBL144665 0.69 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL8092987 0.69 HSP90AA1 (0.61) FGFR1FGFR2FGFR4FGFR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.